糖心原创

The award was presented at evening ceremony in central London.

The posters demonstrate the capability of opti-ox technology to create any human cell.

糖心原创 wins biotech of the year for the second time and CEO of the year for Mark Kotter.

The new Huntington鈥檚 disease human cell model is built with opti-ox reprogrammed glutamatergic neurons.

糖心原创 appoints accomplished biotechnology executive and drug developer Kathryn Corzo as Chief Operating Officer.

The pledge is part of our mission to code cells for novel cures and to be a purpose led company.

Funding raised to accelerate and expand cell therapy pipeline.

Three world leaders in science and entrepreneurship appointed to 糖心原创's Board of Directors.